REGN13335

Phase 2Small molecule

Regeneron

REGN13335 is one of 41 small molecule programs targeting Pulmonary Arterial Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary Arterial HypertensionActive, not recruiting

Pulmonary Arterial Hypertension (PAH)Recruiting

Pulmonary Arterial HypertensionPhase 2

Active, not recruiting

Pulmonary Arterial Hypertension (PAH)Phase 2

Recruiting

Competition

Competitive Landscape

179 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

6 2

Reata

Biogen

Phase 3

1 3

Levitra

Bayer

Phase 3

1 4

Aurlumyn

BBTG International Inc.

Phase 3

8 5

Flolan

Johnson & Johnson

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Inhaled Iloprost

Bayer

Phase 3

1 8

Atrovent

Farxiga

1 10

MS Contin

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Pulmonary Arterial Hypertension (PAH)

NCT07318597

Clinical

Trials by Indication[1]

Intravenous1 trial

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

Completed· Regeneron logo

Regeneron·Phase 1·NCT06137482·56 enrolled

Pulmonary Arterial Hypertension (PAH)1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT07318597·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for REGN13335. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN13335 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN13335. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN13335

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Intravenous1 trial

Pulmonary Arterial Hypertension (PAH)1 trial

References

Drug Info

Quick Facts

Related News